Medicare Enrolled
Dr. Jamal Joudeh, MD
Medical Oncology · Pensacola, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Joudeh from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Joudeh? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Joudeh
Dr. Jamal Joudeh is a medical oncology in Pensacola, FL, with 18 years in practice. Based on federal Medicare data, Dr. Joudeh performed 162,778 Medicare services across 3,285 unique beneficiaries.
Between the years covered by Open Payments, Dr. Joudeh received a total of $15,315 from 44 pharmaceutical and/or device companies across 139 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Joudeh is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice▲ Top 16% volume in FL$ $15,315 industry payments
Medicare Practice Summary
Medicare Utilization ↗162,778
Medicare services
Top 16% in FL for medical oncology
3,285
Unique beneficiaries
$13
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~9,043 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Filgrastim injection (Nivestym) for white blood cells | 30,060 | $0 | $2 |
| Pembrolizumab injection (Keytruda) | 27,800 | $43 | $131 |
| Darbepoetin injection (Aranesp) for anemia | 17,350 | $2 | $21 |
| Iron infusion (Feraheme) | 14,790 | $0 | $6 |
| Azacitidine chemotherapy injection | 12,600 | $0 | $14 |
| Oxaliplatin chemotherapy injection | 8,800 | $0 | $36 |
| Paclitaxel chemotherapy injection | 7,847 | $0 | $1 |
| Anti-nausea injection (aprepitant) | 6,760 | $1 | $8 |
| Anti-nausea injection (fosaprepitant) | 5,850 | $0 | $6 |
| Contrast dye for imaging (iodine-based) | 5,725 | $0 | $3 |
| Denosumab injection (Prolia/Xgeva) | 5,220 | $19 | $46 |
| Epoetin alfa injection (Retacrit) for anemia | 3,020 | $6 | $30 |
| Immune globulin infusion (Octagam) | 2,920 | $34 | $226 |
| Iron infusion (Monoferric) | 2,300 | $16 | $71 |
| Dexamethasone injection (steroid) | 1,810 | $0 | $1 |
| Office visit, established patient (30-39 min) | 1,656 | $95 | $224 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,320 | $1 | $122 |
| Injection, granisetron hydrochloride, 100 mcg | 760 | $0 | $25 |
| Injection, leucovorin calcium, per 50 mg | 598 | $3 | $27 |
| Injection of additional new drug or substance into vein | 559 | $12 | $105 |
| Administration of chemotherapy into vein, 1 hour or less | 517 | $100 | $686 |
| Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | 456 | $92 | $157 |
| Injection, fluorouracil, 500 mg | 404 | $2 | $12 |
| Drug injection, under skin or into muscle | 360 | $11 | $93 |
| Injection, carboplatin, 50 mg | 348 | $2 | $300 |
| Injection, zoledronic acid, 1 mg | 274 | $7 | $462 |
| Injection, gadobenate dimeglumine (multihance), per ml | 190 | $1 | $16 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 187 | $22 | $152 |
| New patient office visit (45-59 min) | 180 | $126 | $343 |
| Office visit, established patient (20-29 min) | 171 | $65 | $148 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 161 | $48 | $304 |
| Administration of additional new drug or substance into vein, 1 hour or less | 143 | $50 | $334 |
| Injection, diphenhydramine hcl, up to 50 mg | 142 | $1 | $5 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 132 | $53 | $205 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 125 | $397 | $638 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 114 | $16 | $97 |
| Administration of chemotherapy into vein, each additional hour | 109 | $22 | $156 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 100 | $1,170 | $4,120 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 73 | $4 | $26 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 56 | $26 | $141 |
| Initial hospital admission, moderate complexity | 52 | $99 | $297 |
| Administration of additional new drug or substance into vein using push technique | 51 | $42 | $281 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 46 | $1 | $19 |
| Hospital follow-up visit, high complexity | 44 | $95 | $232 |
| Ct scan of chest with contrast | 40 | $95 | $1,005 |
| Blood creatinine level | 40 | $5 | $30 |
| CT scan of chest, without contrast | 38 | $89 | $861 |
| Irrigation of implanted venous access drug delivery device | 35 | $18 | $111 |
| Screening mammography | 34 | $125 | $433 |
| Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 34 | $41 | $226 |
| Office visit, established patient, complex (40-54 min) | 33 | $136 | $301 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 33 | $133 | $986 |
| CT scan of abdomen and pelvis with contrast | 32 | $229 | $1,400 |
| Infusion into a vein for hydration, 31-60 minutes | 32 | $24 | $249 |
| Nuclear medicine study whole body with ct scan | 30 | $1,210 | $4,120 |
| Infusion, normal saline solution , 1000 cc | 30 | $2 | $19 |
| 3D screening mammography (tomosynthesis) | 29 | $52 | $226 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 27 | $15 | $91 |
| Injection of drug or substance into vein | 25 | $28 | $240 |
| Diagnostic mammography of both breasts | 23 | $115 | $532 |
| Infusion into a vein for hydration, each additional hour | 22 | $10 | $73 |
| Bone density scan (DEXA) | 14 | $37 | $421 |
| Chest X-ray, 2 views | 13 | $26 | $96 |
| Diagnostic mammography of 1 breast | 12 | $90 | $423 |
| Limited ultrasound scan of 1 breast | 11 | $70 | $355 |
| Complete x-ray of body bones | 11 | $78 | $284 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
12.7% high complexity
85.7% medium
1.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$15,315
Total received (2018-2024)
Avg $2,552/year across 6 years
Top 35% in FL for medical oncology
44
Companies
139
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$9,721 (63.5%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,128 (27.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,465 (9.6%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$1,198
2023$2,928
2022$6,033
2021$1,828
2019$2,019
2018$1,309
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Incyte Corporation
$2,818
Gilead Sciences, Inc.
$2,800
Bayer HealthCare Pharmaceuticals Inc.
$1,590
Karyopharm Therapeutics Inc.
$1,550
G1 Therapeutics, Inc.
$1,289
AstraZeneca Pharmaceuticals LP
$1,048
Aadi Bioscience, Inc.
$1,000
Novartis Pharmaceuticals Corporation
$475
Janssen Biotech, Inc.
$396
Astellas Pharma US Inc
$386
Regeneron Healthcare Solutions, Inc.
$174
Celgene Corporation
$146
Genentech USA, Inc.
$135
PFIZER INC.
$131
BeiGene USA, Inc.
$118
Eisai Inc.
$98
Myriad Genetic Laboratories, Inc.
$88
E.R. Squibb & Sons, L.L.C.
$88
Janssen Scientific Affairs, LLC
$84
GENZYME CORPORATION
$81
Merck Sharp & Dohme LLC
$78
Mirati Therapeutics, Inc.
$78
ABBVIE INC.
$74
Pharmacyclics LLC, An AbbVie Company
$74
Daiichi Sankyo Inc.
$45
Lilly USA, LLC
$45
Alexion Pharmaceuticals, Inc.
$44
EMD Serono, Inc.
$37
Adaptive Biotechnologies Corporation
$36
Myovant Sciences Inc.
$33
Takeda Pharmaceuticals U.S.A., Inc.
$31
CSL Behring
$26
Ipsen Biopharmaceuticals, Inc
$24
ARRAY BIOPHARMA INC
$24
Sumitomo Pharma America, Inc.
$23
Kite Pharma, Inc.
$22
Stemline Therapeutics Inc.
$21
Tempus AI, Inc
$21
Apellis Pharmaceuticals, Inc.
$20
Bayer Healthcare Pharmaceuticals Inc.
$16
Boston Scientific Corporation
$16
SpringWorks Therapeutics, Inc.
$13
Teva Pharmaceuticals USA, Inc.
$12
Janssen Pharmaceuticals, Inc
$9
Top 3 companies account for 47.1% of total payments
Associated products mentioned in payments ›
AFINITOR · Alecensa · BENDEKA · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · CALQUENCE · COSELA · DARZALEX · ERLEADA · Empaveli · Enhertu · Erleada · Fabhalta · Fyarro · Hemlibra · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Idelvion · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · LIBTAYO · LUTATHERA · Lenvima · MEKINIST · MYRISK · NINLARO · Nubeqa · OGSIVEO · OPDIVO · OPDUALAG · ORGOVYX · Onivyde · Orserdu · PLUVICTO · PROMACTA · Pomalyst · REBLOZYL · RYBREVANT · SARCLISA · TAGRISSO · TASIGNA · TECENTRIQ · Tecentriq · ULTOMIRIS · VENCLEXTA · VERZENIO · Venclexta · Vitrakvi · WATCHMAN · XPOVIO · XT CDX · XTANDI · Xtandi · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (64%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Equivalent to $9 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
2
Per 100K population
0.6
County median income
$65,715
Nearest hospital
BAPTIST HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Joudeh is a mixed practice specialist, with above-average Medicare volume (top 16% in FL), and consulting-driven industry engagement, with 18 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Joudeh experienced with filgrastim injection (nivestym) for white blood cells?
Based on Medicare claims data, Dr. Joudeh performed 30,060 filgrastim injection (nivestym) for white blood cells services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Joudeh receive payments from pharmaceutical companies?
Yes. Dr. Joudeh received a total of $15,315 from 44 companies across 139 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Joudeh's costs compare to other medical oncologys in Pensacola?
Dr. Joudeh's average Medicare payment per service is $13. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Joudeh) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Pensacola
Browse medical oncologys in Pensacola ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in FL
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in FL
Which FL medical oncologys receive the most from drug and device companies.
By company
Incyte Corporation Payments to Doctors
See all physicians who received payments from Incyte Corporation.
By company
Gilead Sciences, Inc. Payments to Doctors
See all physicians who received payments from Gilead Sciences, Inc..
By company
Bayer HealthCare Pharmaceuticals Inc. Payments to Doctors
See all physicians who received payments from Bayer HealthCare Pharmaceuticals Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology